Substipharm Biologics to join Emergent Biosolutions in Japanese Encephalitis vaccine production

Substipharm Biologics to join Emergent Biosolutions in Japanese Encephalitis vaccine production
Emergent enters vaccine partnership

Emergent Biosolutions has announced a strategic manufacturing partnership with Substipharm Biologics to support the production of a Japanese Encephalitis vaccine in the U.S.

This collaboration aims to strengthen vaccine availability for the disease in the region, with both companies committing to bolstering supply and facilitating distribution. Further details about timelines and production capacities have not been disclosed.

Emergent Biosolutions recently launched a NARCAN Nasal Spray carrying case and multipacks to support campus opioid overdose preparedness efforts, according to a prior company announcement. The company also committed 2026 Cycle A donations to charitable groups focused on health, scientific education, and veteran support, as highlighted in a recent disclosure. The new partnership with Substipharm Biologics adds to Emergent’s ongoing public health initiatives.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.